Ethics, Equity, and the Germline Question
He Jiankui, returning secondary findings, ancestry bias, and the unresolved policy frontier.
What's covered
- T01Germline editing: He Jiankui case, WHO advisory committee, US National Academies framework
- T02Secondary-finding return: ACMG SF v3.2 (81 genes), patient choice, pediatric autonomy
- T03Direct-to-consumer testing landscape and the 23andMe data-stewardship aftermath
- T04Genomic discrimination: GINA scope and gaps (life, disability, long-term care insurance)
- T05Ancestry bias in reference data, PRS, variant interpretation
- T06Reproductive technologies: PGT-M, PGT-A, PGT-P (polygenic embryo screening)
By the end of this module you will be able to
- L01State the international policy consensus on heritable genome editing (2020 NASEM/Royal Society/WHO).
- L02Counsel a patient who has been offered polygenic embryo screening through an IVF clinic.
- L03Explain the limits of GINA's protections and where discrimination remains legal in the US.
What you should walk away believing
- International scientific bodies have converged on a 'not now, possibly later under strict conditions' position on heritable genome editing — He Jiankui's 2018 work was condemned across the board.
- ACMG SF v3.2 currently lists 81 genes with strong evidence for actionable secondary-finding return; opt-in/opt-out is the standard at consent.
- GINA does not cover life, disability, or long-term care insurance — material counseling implication.
- Polygenic embryo screening has been commercialized (Genomic Prediction → LifeView, Orchid) without consensus support; risk-stratification accuracy and ethical concerns are unresolved.
What this means at your level
Genomic medicine produces information that can affect a person's family, insurance, reproduction, and identity. There is broad international agreement against editing the human germline at this stage. There is broad disagreement about almost everything else — which findings to return, who pays, what employers and insurers can ask, and how reproductive screening should be regulated.
Three discussions to have, in order: (1) primary results — what the test was ordered for; (2) secondary findings — the ACMG opt-in list, with explicit consent; (3) downstream implications for family members, insurance, and reproduction. In the US, document GINA's gaps in writing. For families considering PGT-P, present the actual evidence (modest risk reclassification, untested in children, ethical critique) without either dismissing it or endorsing.
Active policy fronts: WHO Human Genome Editing registry (2024 update), Council of Europe Oviedo Convention review, EU AI Act intersection with PRS-based clinical decision support, and FDA guidance on 'in silico clinical trials' for variant interpretation. Ancestry-equity work (All of Us, H3Africa, GenomeAsia, MENA Genome Project) is closing reference gaps but slowly.
Polygenic embryo screening lets parents pick smart, healthy children.
Currently marketed PGT-P scores explain a small fraction of variance, are calibrated almost exclusively in European-ancestry samples, and re-rank embryos by amounts often within statistical noise. Major bodies (ESHRE, ASRM, ACMG) have all expressed concern.
What the data say
Test yourself
Key terms & abbreviations
- GINAGenetic Information Nondiscrimination Act (US, 2008)
- Federal law prohibiting genetic discrimination in health insurance and employment. Excludes life, disability, long-term care insurance.
- ACMG SF
- American College of Medical Genetics minimum list of genes for opportunistic secondary-finding return in clinical sequencing.
- PGT-PPreimplantation Genetic Testing — Polygenic
- Embryo selection using polygenic risk scores; commercially offered, not endorsed by major reproductive-medicine bodies.
- Heritable genome editing
- Genome editing in gametes or embryos with germline transmission. Subject to international moratorium consensus for clinical use.
Anchor references
- Heritable Human Genome Editing — International Commission report — NASEM/Royal Society 2020
- ACMG SF v3.2 list for reporting of secondary findings — Miller et al., Genet Med 2023